MedPath

Short Course Radiation Therapy in Palliative Treatment of Esophageal Cancer

Not Applicable
Conditions
Radiotherapy
Esophageal Cancer
Palliative Care
Interventions
Radiation: standard treatment
Radiation: short course treatment
Registration Number
NCT03804203
Lead Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Brief Summary

Aim of the study is to assess efficacy of a short course radiation treatment in patients with symptomatic esophageal malignant lesions

Detailed Description

Standard treatment for esophageal lesions (3000 cGy in 10 daily fractions of 300 cGy each) is compared with experimental treatment (2000 cGy in 4 fractions of 500 cGy twice a day) to demonstrate non-inferiority of this scheme

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
98
Inclusion Criteria
  • symptomatic esophageal malignant lesions (primary solid tumors or metastases from solid tumor);
  • age>18 years;
  • ECOG performance status 0-3
  • no changes in supportive care in the week before radiotherapy
Exclusion Criteria
  • pregnancy
  • previous irradiation of the same region

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
standard treatmentstandard treatmentpatients in this group are treated with 3000 cGy in 10 daily fraction
short course treatmentshort course treatmentpatients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
Primary Outcome Measures
NameTimeMethod
Efficacy of palliation using the short course scheme compared with the standard scheme: Likert scale3 months

reduction of initial symptoms after radiotherapy, assessed with Likert scale (dysphagia, odynophagia, regurgitation, chest-back pain are evaluated as none-mild-moderate-severe)

Secondary Outcome Measures
NameTimeMethod
late toxicity in the two treatment groups12 months

incidence of treatment-related adverse events in the two arms of the study registered using RTOG/EORTC Late Radiation Morbility Scoring Schema

acute toxicity in the two treatment groups3 months

incidence of treatment-related acute adverse events in the two arms of the study registered using Cooperative Group Common Toxicity Criteria

Quality of Life (QoL): EORTC questionnaire C15-PAL12 months

changes in QoL after the treatment assessed using European Organization for Research and Treatment of Cancer (EORTC) questionnaire C15-PAL (a specific questionnaire from EORTC developed to assess the quality of life of palliative cancer care patients)

Trial Locations

Locations (1)

Radiation Oncology Center, Department of Experimental, Diagnostic and Speciality Medicine- DIMES, University of Bologna, S.Orsola-Malpighi Hospital

🇮🇹

Bologna, BO, Italy

© Copyright 2025. All Rights Reserved by MedPath